圣诺生物2025年净利同比预增204.42%至280.53%

Core Viewpoint - Shengnuo Biotech (688117) forecasts a significant increase in net profit for 2025, projecting a range of 152 million to 190 million yuan, representing a year-on-year growth of 204.42% to 280.53% [1] Group 1 - The company attributes the expected profit growth to the successful implementation of its annual business strategy, focusing on the realization of its production capacity while expanding both domestic and international markets [1] - The demand for the company's peptide raw material business has been steadily increasing, contributing to the overall performance improvement [1] - The anticipated growth further enhances the company's global competitiveness in the peptide pharmaceutical market [1]